Andrea Duminuco retweeted
It’s about time we remove CNS ppx in DLBCL from the NCCN guidelines.
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Andrea Duminuco retweeted
The vlogcast features Dr Patrick Harrington, Consultant Haematologist, Guy’s & St Thomas’ Hospital, discussing the new study on thrombosis risk in MPN patients using QRISK3 Score. Dr Harrington explains the research the team at Guy’s Hospital have done to see if a new way of assessing patients’ risk of thrombosis (clotting) called QRISK3, could be a useful tool for patients and their clinicians to judge their risk of having a clot. The research shows that QRISK3 is an accurate way of assessing risk and is likely to lead to it being used by MPN clinicians from now on.
The Study:
Used the QRISK3 score, a tool developed to estimate a person’s 10-year risk of heart attack or stroke, factoring in age, ethnicity, location, and various health metrics
Analyzed data from >1000 ET and PV patients treated at Guy’s & St Thomas’ Hospital
Patients had a median 8-year follow-up.
Practical Implications for Patients:
Patients can calculate their QRISK3 score online qrisk.org
If the score is elevated, it’s worth discussing modifying risk factors (like BMI, cholesterol, blood pressure) with a GP
Patients with high scores but no current cytoreductive therapy should talk to their haematologist, especially those around “borderline” age (50s–60s)
Next Steps:
The team hopes to expand the study across more centres and internationally to validate findings beyond a single hospital
You can watch the vlogcast, read the study and calculate your risk via the link here - linktr.ee/Mpnvoice
Andrea Duminuco retweeted
Check out our paper looking at QRISK3 score as a predictor of thrombotic risk in MPN patients . Great collaborative work led by Patrick Harrington and Andrea Duminuco @ADuminuco #mpn
nature.com/articles/s41375-0…
Proud to share our recent study published on Leukaemia.
QRISK3 score can identify MPN patients with higher risk of TE based on CV risk factors that may benefit of early cytoreduction
nature.com/articles/s41375-0…
@drpharrington @harrisoncn1
Andrea Duminuco retweeted
#mdpijcm
#Editor’s Choice Paper💫
#HighAltmetricScore
Views 7373💥, Citations 3
Emergencies in #Hematology: Why, When and How I Treat?
by Andrea Duminuco et al. @ADuminuco
👏mdpi.com/3085168
@MediPharma_MDPI
Paper of impressive importance. It’s time to looking beyond in BMT panorama for MF patients.
Great work @NicoGagelmann and team
🎉Finally published🎉
Clearance of driver mutations after transplantation for myelofibrosis
@NEJM nejm.org/doi/full/10.1056/NE…
Andrea Duminuco retweeted
Dichiarazione del Presidente della Repubblica Sergio #Mattarella:

ALT L’Italia è un grande Paese democratico e devo ribadire, con le parole adoperate in altra occasione, il 7 ottobre 2022, che “sa badare a sé stessa nel rispetto della sua Costituzione”. Chiunque, particolarmente se, come annunziato, in procinto di assumere un importante ruolo di governo in un Paese amico e alleato, deve rispettarne la sovranità e non può attribuirsi il compito di impartirle prescrizioni. Sergio Mattarella
Andrea Duminuco retweeted
CONGRESS | #SOHO2024
Prithviraj Bose, @MDAndersonNews, discusses key data on available JAK inhibitors to help optimize their selection for treatment of #myelofibrosis. Generally, ruxolitinib and fedratinib are better suited for the myeloproliferative phenotype, while momelotinib and pacritinib are more for the myelodepletive phenotype. However, he argues that momelotinib could be effective for both.
@bose_prithviraj #MPNsm #MedicalCongress
Looking into the future in MF approach!
Brilliant presentation from J. Mascarenhas
#SOHO24
2
85
The importance of management of CV risk factors in PV and ET patients also presented at #SOHO24
onlinelibrary.wiley.com/doi/…
@MPN @MPNVoice @GSTTnhs
Travelling for #Houston and #SoHo24. Excited to be again in contact with amazing colleagues and share the knowledge in #Hematology 🩸
#endcancer #MDACC
1
3
262
Andrea Duminuco retweeted
“La felicità è lavoro, ricerca, impegno, capacità di osservare, di analizzare noi stessi e ciò che ci circonda. Felicità è accogliere, è assunzione di responsabilità."
L'intervento finale dei Presidenti #AGESCI a #RN24 nell'ampio servizio di @agensir.
agensir.it/italia/2024/08/26…
Andrea Duminuco retweeted
"Siete capi. L’Agesci è una delle poche realtà dove questo termine è evidente, libero da confronti e competizioni perché come deve essere, di solo servizio."
L'omelia del card. #Zuppi alla Route nazionale delle Comunità capi con 18mila capi #scout. #RN24
chiesacattolica.it/card-zupp…
Andrea Duminuco retweeted
Le Comunità capi stanno arrivando a Verona per la Route nazionale #RN24! Segui con noi fino a domenica questo evento storico per i #50anniAgesci anche sui canali web e social:
instagram.com/agesci.routena…
instagram.com/agesci.naziona…
rn24.agesci.it/ e agesci.it
Andrea Duminuco retweeted
Today @cic1427 a patient with myelofibrosis started for the 1st time in Europe a treatment with an anti-mutant CALR bispecific antibody🤞#MPNsm
@HopSaintLouis @APHP @univ_paris_cite @Institut_IRSL @Inserm @Institut_cancer @CancerParisNord #immunotherapy
This is time to looking beyond. Machine learning and artificial intelligence confirm in our research the importance of CV risk factors in thrombotic risk for MPN diseases. Excited to share our results
#MPN #AI
@GSTTnhs @harrisoncn1 @drpharrington
onlinelibrary.wiley.com/doi/…



























